Japanese trial compared lytics for bridging before endovascular thrombectomy ...

PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...

The researchers observed no significant differences between tenecteplase and alteplase in terms of effectiveness or safety outcomes for the overall cohort after adjustment for covariates. HealthDay ...

Please provide your email address to receive an email when new articles are posted on . Tenecteplase was noninferior to alteplase for acute ischemic stroke when given within 4.5 hours of symptom onset ...

Researchers found that the percentage of patients achieving a score of 0 or 1 on the modified Rankin scale at 90 days was 40.3 and 26.3% in the alteplase and standard medical treatment groups, ...

LOS ANGELES -- Tenecteplase (TNKase) is a more powerful thrombolytic for large vessel acute ischemic stroke than alteplase (Activase) but just as safe, the EXTEND-IA TNK trial showed. Tenecteplase ...

A noninferiority trial comparing two doses of thrombolytic therapy with the tissue plasminogen activator (tPA) alteplase has failed to demonstrate that low-dose therapy is as effective as ...

Find out how to take Alteplase (drug) and its dose. Describes the best time to take the drug and precautions if any that should be followed. We recommend consulting your doctor to verify the ...

Roche’s subsidiary, Genentech, issued the voluntary recall of the anti-stroke drug because of compromised vials containing sterile water that were packaged with the drug. Roche’s Genentech is ...

LOS ANGELES — Not only is tenecteplase a cheaper and more convenient thrombolytic agent than alteplase, but new research suggests it also leads to better outcomes in stroke patients selected for ...